During the last session, Generation Bio Co (NASDAQ:GBIO)’s traded shares were 0.4 million, with the beta value of the company hitting 2.71. At the end of the trading day, the stock’s price was $1.15, reflecting an intraday gain of 3.60% or $0.04. The 52-week high for the GBIO share is $4.65, that puts it down -304.35 from that peak though still a striking 34.78% gain since the share price plummeted to a 52-week low of $0.75. The company’s market capitalization is $76.81M, and the average intraday trading volume over the past 10 days was 0.66 million shares, and the average trade volume was 248.05K shares over the past three months.
Generation Bio Co (GBIO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.86. GBIO has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.23.
Generation Bio Co (NASDAQ:GBIO) trade information
Generation Bio Co (GBIO) registered a 3.60% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.60% in intraday trading to $1.15, hitting a weekly high. The stock’s 5-day price performance is 3.60%, and it has moved by -16.06% in 30 days. Based on these gigs, the overall price performance for the year is -38.50%. The short interest in Generation Bio Co (NASDAQ:GBIO) is 1.78 million shares and it means that shorts have 7.62 day(s) to cover.
Generation Bio Co (GBIO) estimates and forecasts
Statistics show that Generation Bio Co has underperformed its competitors in share price, compared to the industry in which it operates. Generation Bio Co (GBIO) shares have gone down -46.76% during the last six months, with a year-to-date growth rate less than the industry average at 10.71% against 16.80. In the rating firms’ projections, revenue will increase 207.23% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2.92M as predicted by 6 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 1.4M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.88M and 4.06M respectively. In this case, analysts expect current quarter sales to grow by 1.35% and then drop by -65.51% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -20.44%. While earnings are projected to return 0.20% in 2025.
GBIO Dividends
Generation Bio Co is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Generation Bio Co (NASDAQ:GBIO)’s Major holders
Generation Bio Co insiders own 14.51% of total outstanding shares while institutional holders control 82.94%, with the float percentage being 97.02%. PRICE T ROWE ASSOCIATES INC /MD/ is the largest shareholder of the company, while 118.0 institutions own stock in it. As of 2024-06-30, the company held over 9.51 million shares (or 14.3205% of all shares), a total value of $26.83 million in shares.
The next largest institutional holding, with 8.28 million shares, is of ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC’s that is approximately 12.4628% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $23.35 million.
